CRL 187.9 (+0.97%)
US1598641074Medical Diagnostics & ResearchDiagnostics & Research

Charles River Laboratories (CRL) Competitor Comparison

We are evaluating the key criteria listed to compare Charles River Laboratories (CRL) against its competitors in the Diagnostics & Research industry.

Linearity 5 years - CRL ranking 15 / 58

These are the competitors of Charles River Laboratories in the industry Diagnostics & Research ranked by linearity 5 years
1. Co-Diagnostics CODX
66.71
2. Qiagen QGEN
48.8
3. Ortho Clinical Diagnostics Holdings OCDX
33.4
4. DarioHealth DRIO
31.71
5. Inotiv NOTV
26.32
6. Syneos Health SYNH
24.79
7. Anixa Biosciences ANIX
17.53
8. CareDx CDNA
17.14
9. Heska HSKA
15.42
10. Fulgent Genetics FLGT
13.74
11. Icon ICLR
9.31
12. DexCom DXCM
9.28
13. Olink Holding OLK
8.53
14. Pacific Biosciences of California PACB
8.28
15. Charles River Laboratories CRL
7.54
16. NeoGenomics NEO
7.29
17. Trinity Biotech TRIB
6.29
18. Personalis PSNL
6.09
19. IQVIA Holdings IQV
5.98
20. Aspira Womens Health AWH
5.9
21. Myriad Genetics MYGN
5.84
22. Exact Sciences EXAS
5.74
23. Bioventus BVS
5.67
24. PerkinElmer PKI
4.97
25. Twist Bioscience TWST
4.75
26. IDEXX Laboratories IDXX
4.69
27. Sera Prognostics SERA
4.49
28. Neogen NEOG
4.33
29. Illumina ILMN
4.22
30. Sotera Health SHC
4.18
31. Quest Diagnostics DGX
4.11
32. Agilent Technologies A
3.87
33. Guardant Health GH
3.81
34. Enzo Biochem ENZ
3.68
35. Interpace Biosciences IDXG
3.64
36. Mettler-Toledo MTD
3.63
37. Thermo Fisher Scientific TMO
3.48
38. Laboratory Corp of America Holdings LH
3.39
39. National Research NRC
3.04
40. Danaher DHR
2.95
41. Waters WAT
2.71
42. Precipio PRPO
2.58
43. Psychemedics PMD
2.56
44. Neuronetics STIM
2.28
45. Global Cord Blood CO
2.23
46. MDxHealth MDXH
2.08
47. Exagen XGN
2.04
48. MaxCyte MXCT
2.02
49. Biodesix BDSX
1.93
50. bioAffinity Technologies BIAF
1.9
51. Prenetics Global PRE
1.81
52. Organovo Holdings ONVO
1.6
53. SeqLL SQL
1.38
54. Meridian Bioscience VIVO
0.99
55. Lantheus Holdings LNTH
0.67
56. Natera NTRA
0.63
57. Medpace Holdings MEDP
0.58
58. RadNet RDNT
0.34

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.